Published on
January 10, 2020
- 00:33 GMT
Samsung Bioepis and AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing ...
SB12 (also referred to as AMT904) is an eculizumab biosimilar candidate for the treatment of paroxysmal nocturnal hemoglobinuria The only biosimilar candidate referencing Soliris® (eculizumab)1 to be granted IND approval in China INCHEON, Korea and …
Distribution channels:
Banking, Finance & Investment Industry, Media, Advertising & PR
...
